| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 12/20/2001 | WO2001096323A1 Serine protease inhibitors |
| 12/20/2001 | WO2001096322A1 Diamino phenothiazine derivatives and composition comprising same |
| 12/20/2001 | WO2001096311A2 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 12/20/2001 | WO2001096310A1 Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists |
| 12/20/2001 | WO2001096308A1 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| 12/20/2001 | WO2001096305A1 Serine protease inhibitors |
| 12/20/2001 | WO2001096302A1 Piperidines for use as orexin receptor antagonists |
| 12/20/2001 | WO2001096299A2 Indole derivatives and their use as 15-lipoxygenase inhibitors |
| 12/20/2001 | WO2001096298A2 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 12/20/2001 | WO2001096297A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 12/20/2001 | WO2001096296A1 Serine protease inhibitors |
| 12/20/2001 | WO2001096295A2 2-cyanopyrrolidine derivatives and their use as medicaments |
| 12/20/2001 | WO2001096289A1 Sulfonamide derivatives |
| 12/20/2001 | WO2001096286A2 Urokinase inhibitors |
| 12/20/2001 | WO2001096283A2 Hiv integrase inhibitors |
| 12/20/2001 | WO2001095945A2 Prodrug compounds cleavable by thimet oligopeptidase |
| 12/20/2001 | WO2001095943A2 Prodrug compounds with an oligopeptide having an isoleucine residue |
| 12/20/2001 | WO2001095942A2 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 12/20/2001 | WO2001095937A2 Phytoestrogenic isoflavone compositions |
| 12/20/2001 | WO2001095932A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR |
| 12/20/2001 | WO2001095931A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR Xa INHIBITOR |
| 12/20/2001 | WO2001095929A2 Interferon for treatment of multiple sclerosis |
| 12/20/2001 | WO2001095925A1 Pharmaceutical anti-inflammatory aerosol formulation |
| 12/20/2001 | WO2001095924A2 Method for treating a movement disorder |
| 12/20/2001 | WO2001095923A1 Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root |
| 12/20/2001 | WO2001095921A1 Cytokine production inhibitors, agents for protecting and promoting liver function, anti-inflammatory agents, immunosuppressants, drugs, cosmetics, foods and food materials |
| 12/20/2001 | WO2001095919A2 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| 12/20/2001 | WO2001095911A1 Protease inhibitors |
| 12/20/2001 | WO2001095908A1 Protoberberine derivatives which inhibit activity of the mitogen-activated protein kinase |
| 12/20/2001 | WO2001095906A1 Treatment and prevention of cardiac insulin resistance associated conditions |
| 12/20/2001 | WO2001095905A1 Inhibitor for enzyme having two divalent metal ions as active centers |
| 12/20/2001 | WO2001095899A2 Pharmaceutical compositions comprising cannabidiol derivatives |
| 12/20/2001 | WO2001095895A2 Methods of potentiating organic nitrates having vasodilating activity and formulations for the same |
| 12/20/2001 | WO2001095893A1 Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095892A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095884A2 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 12/20/2001 | WO2001095882A1 Novel aqueous anti-inflammatory pharmaceutical formulation |
| 12/20/2001 | WO2001095880A1 Novel pharmaceutical formulation suitable for nebulisation |
| 12/20/2001 | WO2001095879A1 Novel aqueous anti-inflammatory pharmaceutical formulation |
| 12/20/2001 | WO2001095859A2 Novel heterocyclic analogs of diphenylethylene compounds |
| 12/20/2001 | WO2001095785A2 Modulation of immune response and methods based thereon |
| 12/20/2001 | WO2001095739A2 Diet which induces ketosis in a canine or feline |
| 12/20/2001 | WO2001095711A2 Transgenic mice containing nuclear hormone receptor gene disruptions |
| 12/20/2001 | WO2001088108A8 Neuronal serine-threonine protein kinase |
| 12/20/2001 | WO2001087838A8 Cyclohexane derivatives and their use as therapeutic agents |
| 12/20/2001 | WO2001058896A8 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 12/20/2001 | WO2001055725A3 Diagnosis of tauopathies determining tau/phospho-tau ratio |
| 12/20/2001 | WO2001053518A3 Method of assessing the viability of a cell |
| 12/20/2001 | WO2001049689A3 NOVEL SUBSTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM |
| 12/20/2001 | WO2001044207A3 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 12/20/2001 | WO2001023592A3 Methods for making recombinant proteins using apoptosis inhibitors |
| 12/20/2001 | WO2001022969A3 Vasopressin agonist formulation and process |
| 12/20/2001 | WO2001019770A3 Rxr modulators with improved pharmacologic profile |
| 12/20/2001 | WO2001016108A3 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 12/20/2001 | WO2001015693A3 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 12/20/2001 | WO2000068387A3 Nucleic acids and proteins with interferon-beta activity |
| 12/20/2001 | WO1999063976A3 Liver-selective glucocorticoid antagonist for treating diabetes |
| 12/20/2001 | US20010053853 Alkanoic acid derivative; integrin receptor antagonist |
| 12/20/2001 | US20010053851 Antidiabetic agents |
| 12/20/2001 | US20010053844 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/20/2001 | US20010053793 Administering dehydroascorbic acid |
| 12/20/2001 | US20010053791 Glycogen phosphorylase inhibitor |
| 12/20/2001 | US20010053788 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
| 12/20/2001 | US20010053783 Central nervous system disorders |
| 12/20/2001 | US20010053782 Pyrrolo[2,3-d]pyrimidine compounds |
| 12/20/2001 | US20010053778 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 12/20/2001 | US20010053777 Synergistic mixture containing alpha 2-antagonist agent and neuropsychic drug |
| 12/20/2001 | US20010053768 Gene therapy using replication competent targeted adenoviral vectors |
| 12/20/2001 | US20010053536 cDNA clone HDPBI30 that encodes a novel human 7-transmembrane receptor |
| 12/20/2001 | US20010053370 Parkinson's disease treatment |
| 12/20/2001 | US20010053369 Treating a movement disorder by intracranial administration of a neurotoxin, especially a botulinium toxin |
| 12/20/2001 | US20010053357 Peptide having an amino acid sequence corresponding to an amino acid sequence of a V-domain of a receptor for advanced glycation endproduct. |
| 12/20/2001 | US20010053355 Treated monocytes incubated to maximize number of functional dendritic cells; then incubated with disease effector agents to enhance the presentation of at least one disease-causing antigen expressed by the disease effector agents. |
| 12/20/2001 | US20010053351 Inhibition of GSK-3 beta |
| 12/20/2001 | US20010053347 Methods and compositions for preventing and treating chronological aging in human skin |
| 12/20/2001 | DE10037272A1 Identifying agents for treating cardiovascular disease, comprises determining the ability of potential agents to modify interaction between beta3 endonexin and beta3 integrin |
| 12/20/2001 | DE10029015A1 Coagulation Factor Xa inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative |
| 12/20/2001 | DE10029014A1 Urokinase inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative |
| 12/20/2001 | DE10024171A1 Neuronale Serin-Threonin-Protein-Kinase Neuronal serine threonine protein kinase |
| 12/20/2001 | CA2719176A1 2-cyanopyrrolidine derivatives and their use as medicaments |
| 12/20/2001 | CA2436116A1 Treatment and prevention of cardiac insulin resistance associated conditions |
| 12/20/2001 | CA2415369A1 Thromboxane receptor antagonist containing formulations for potentiating organic nitrates having vasodilating activity |
| 12/20/2001 | CA2413149A1 Prodrug compounds with isoleucine |
| 12/20/2001 | CA2413077A1 Interferon for treatment of multiple sclerosis |
| 12/20/2001 | CA2412979A1 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 12/20/2001 | CA2412857A1 Hiv integrase inhibitors |
| 12/20/2001 | CA2412663A1 A human homologue of the dbf4/ask1 protein, nucleic acids, and methods related to the same |
| 12/20/2001 | CA2412632A1 Hmg-coa reductase inhibitors and method |
| 12/20/2001 | CA2412623A1 Tetrapyrroles |
| 12/20/2001 | CA2412618A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 12/20/2001 | CA2412462A1 6,5-fused bicyclic heterocycles |
| 12/20/2001 | CA2412353A1 Protease inhibitors |
| 12/20/2001 | CA2412316A1 Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root |
| 12/20/2001 | CA2412257A1 Pro-apoptotic fragments of the dengue virus envelope glycoproteins |
| 12/20/2001 | CA2412223A1 Compositions and methods for the therapy and diagnosis of colon cancer |
| 12/20/2001 | CA2412216A1 Lactam inhibitors of factor xa and method |
| 12/20/2001 | CA2412165A1 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 12/20/2001 | CA2411967A1 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 12/20/2001 | CA2411811A1 Sulfonamide derivatives |
| 12/20/2001 | CA2411805A1 Serine protease inhibitors |